The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Taken from ADVFN BB - Brasso3
Http://chimagents.com/
CHIMagents is a company of experienced and committed individuals building a portfolio of challenge agents to be used in controlled human infection studies.
Controlled human infection studies are becoming more-and-more important for pharmaceutical companies to take Go/No-Go decisions in the development track of potential vaccines and anti-viral drugs.
Together with Key Opinion Leaders and Subject Matter Experts in the field, CHIMagents identify relevant strains and guide development and manufacturing of new challenge agents according to (c)GMP to ensure they are authorised for use in clinical trials in the EU and US.
CHIMagents – experts in Controlled Human Infection Models.
What does all this mean in real terms? Adrian wildfire is director of strategy at hvivo and CEO of chimagents
Whatever happens with the "merger' I Bet it makes the SP go down, I've had a real bad run of luck this Month.
If there’s no seller we’ll be going up fast. If there is we’ll stay flat
My understanding is that at the moment we do not have a challenge study for covid 19 developed as yet. We may have a pipeline of 12 customers/studies but only when the model is complete, it was mothballed years ago due to lack of commercial interest. Perhaps we need this guy on board , being smart he maximised his remuneration this way, set his own terms around 2 months ago by the looks of it. We need the working model badly, extra talent will not hurt but add value, credibility, looks very well connected.
I guess we should all sell for a slight profit or a slight loss . Or Not
Why is a director of the company dropping news on twitter and not through a RNS?
Great to come home and see a decent rise today. :)
It wasn't on twitter and it was announced post market
As long as it's announced before 8am with an RNS it's not a problem regulatory speaking..
Sorry, Gotta, but not been home long and was just reading through the days posts. Saw your's headed "big news" and the next thing on the thread was a link to a tweet. Didn't see any RNS above so that was all I had to go on.
So where has this been announced? Cheers.
It's a screenshot from a LinkedIn post published earlier this evening
Don't forget Chim has two directors and the other guy is pretty impressive as well. https://www.linkedin.com/in/martinschuttencvad/en
Re Adrian Wildfire "Adrians back....we hired him back"
I hope to see an RNS too. But do not expect any serious financials. I am sure the CHIM guys are getting a decent package that includes options. I have no problem with that.
It's all about getting the challenge studies up and running. THAT'S the real news